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Introduction
The World Health Organization (WHO) has reported chronic liver disease to be 
responsible for 1.4 million deaths worldwide in 2002. 
Hepatitis C virus (HCV) stands as one of the most 
important etiologies of chronic liver disease and is 
an emerging infection in the world and in Iran (1). It 
seems that less than 1% of Iranians are infected with 
HCV infection (2). The control of HCV is possible 
and it needs to be eradicated with the best approved 
drugs (3). Hepatitis B virus (HBV) infection is also 
an important health problem worldwide and about 
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Background and Aims: The main purpose of treating and caring for patients with chronic viral hepatitis is to promote life 
satisfaction and a feeling of well-being in patients suffering from this disease. The aim of this study was to evaluate the 
effect of education on quality of life in patients with chronic hepatitis who were treated with Interferon alpha.
Methods: This quasi-experimental study was conducted on 60 patients with viral hepatitis. The intervention included 
teaching them the method of self injection of Interferon alpha 2 b, giving them educational pamphlets and then following 
their continuing treatment with interferon. Patients were randomly assigned to two 30-patient groups. The data- gather-
ing tool was a demographic characteristics questionnaire and the Quality of Life Questionnaire for Patients with Chronic 
Liver Disease (CLDQ). The educational program was done in four 45- minute sessions for the case group and their rela-
tives. The follow-up period was 12 weeks. Quality of life in patients with chronic hepatitis was measured before initiating 
interferon therapy, and after the educational period. Quality of life in the two groups was compared.
Results: The total quality of life score in the two groups before therapy did not show any significant difference 
(P = 0.351); while 12 weeks after education there was a significant difference between the two groups (P < 0.001) in 
three items including abdominal symptoms (P = 0.01), worry (P < 0.001) and emotional factors (P < 0.001). The other 
three items did not show a significant difference between the two groups. The total quality of life score in the case group 
was significantly different before and after education (P < 0.001), and improved after education. The total quality of life 
score in the control group did not differ significantly after 12 weeks (P = 0.143).
Conclusions: Planning short and simple educational programs has a significant effect on the patient’s control of his/her 
disease and its side effects; and can improve quality of life, life satisfaction, and mechanisms of coping with treatment 
in patients with viral hepatitis.
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1,400,000-2,000,000 patients suffer from it in Iran 
(4). The main effective drugs in the treatment of 
HCV infection is alpha interferon plus ribavirin and 
alpha interferon is also one of the approved therapies 
in chronic hepatitis B (5, 6). Several studies have 
documented that impaired health-related quality of 
life (HRQoL) is associated with chronic hepatitis B 
and C (7, 8). Studies have shown that the progression 
of liver disease and ineffective antiviral therapies 
increasingly affect the quality of life, and the mental 
and physical well-being of patients (9). The side effects 
of interferon therapy, including an influenza-like 
syndrome, affect the quality of life of patients as well 
(10). The quality of life effects of treatment regimens 
also affect adherence to treatment regimens (11). 
During therapy with alpha-2b interferon, patients 
should be closely monitored for side effects (10), so 
appropriate and timely supervision during treatment 
is necessary to limit these effects (11). Frequently 
treatment causes fatigue, muscular pain, influenza-
like symptoms, changes in the mental status and 
sexual desires of the patient, which will negatively 
affect the patient’s life, social communication and 
abilities (12). The importance of these side effects 
forms the basis of the physician’s and the patient’s 
decision-making regarding the continuation of the 
therapy, or of the cessation of the course of therapy 
before its completion. Termination of therapy before 
its completion shows the patient’s intolerance (12). 
Side effects of Interferon alpha begin a few hours 
after its administration and the patient develops 
tolerance in a few weeks with continuation of therapy 
(13). Patient education and effective treatment are 
the cornerstones for enabling the patient to adhere 
to a therapeutic regimen. Monitoring the patient 
and dose adjustment during the treatment period is 
necessary (14). At times lack of awareness about the 
route of application results in early termination of the 
treatment (12); as a result, a study of the education of 
the patient in the proper method of the self- injection 
of interferon and the method of familiarizing him or 
her with the side effects and strategies of coping is 
essential and will lead to an improved quality of life. 
This study had been conducted for these reasons.
Our primary goal was to study the effect of 
education on the quality of life of the patient suffering 
from chronic hepatitis B and C under treatment with 
Interferon alpha.
Materials and Methods
This is a quasi-experimental study in a pretest-
posttest method conducted at Tehran Hepatitis Center- 
Baqiyatallah Research Center for Gastroenterology 
and Liver Diseases. Sampling was nonrandomized and 
based on sample characteristics (age 18-60 yrs, absence 
of other infections and chronic diseases, first time 
treatment for Interferon alpha therapy and absence of 
cirrhosis). Sixty patients were randomly assigned to the 
two 30-patient groups of cases and controls. Following 
referral to Tehran Hepatitis Center, patients fulfilling 
our selection criteria and willing to participate in the 
study were assigned to the case and control groups one 
after the other. The Quality of Life Questionnaire for 
Patients with Chronic Liver Disease (CLDQ) and the 
demographic information of the patients were filled 
out anonymously and codes were used with the help 
of the researcher.
The CLDQ is the first tool to assess quality of life 
in chronic liver disease patients reasonably adjusted 
to include fatigue, activity, emotional symptoms, 
abdominal symptoms, systemic symptoms and worry. 
The scores are graded from 1 to 7 for each category 
making the minimum possible scores 29 and the 
maximum 203. The validity and reproducibility of 
this questionnaire had been previously studied in Iran 
(15, 16). The eliability of the CLDQ was measured 
by internal consistency using Cronbach’s alpha test 
with a reported consistency of over 95%. 
Cases were asked to write down their free time 
on the back of the questionnaire to set up times 
for their education classes. These classes were held 
once a week and in each class educational pamphlets 
were distributed among the cases. Follow-up of the 
patients was done as self-reporting with in-person 
attendance every month. Each educational session 
had a maximum of 6 patients and 6 accompanying 
persons.. These accompanying persons had a 
supportive care role. The sequence of the classes was 
as follows: 
In the first session, the goals of our study, the nature 
of their disease, transmission routes, the diagnosis 
and treatment of their disease were explained and 
pamphlets were distributed to the patients. In the 
second session, the effect of interferon therapy on 
their disease, the frequent side effects after injection, 
methods of protecting themselves and controlling 
these side effects were explained and pamphlets were 
distributed. In the third session, the method of the 
self-injection of interferon was explained and the 
patients’ questions were answered. A pamphlet was 
also given out. In the fourth session, the injection 
of interferon by the patient was observed and their 
problems, if any, were corrected. Educational sessions 
were held for a month and patients were followed 
for 12 weeks. At the time of entering the study and 
12 months after initiation of therapy, patients were 
asked to fill the quality of life questionnaire in both 
groups (case and control). The results were analyzed 
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by SPSS (Version 13) using chi-square, Fisher’s exact, 
Mann-Whitney and Wilcoxon tests. For ethical 
issues, after the study, the educational pamphlets 
were also distributed to the control group and the 
correct method of injection of interferon was also 
taught to them. 
Results
The demographics data of the patients is shown 
and compared in Table 1. As is shown, no significant 
difference was observed between the two groups in 
this regard.
The Quality of Life Questionnaire for Chronic 
Liver Disease included 6 items: fatigue, activity, 
emotional symptoms, abdominal symptoms, systemic 
symptoms and worry, which were separately analyzed 
in the two groups before and after our intervention. 
Quality of life scores before and after intervention 
within groups has been shown in Table 2. Quality of 
life scores before and after intervention between the 
two groups has been shown in Table 3.
The systemic symptoms of the control group 
were significantly reduced after 12 weeks (P = 0.04) 
but other aspects including abdominal symptoms (P 
= 0.94), fatigue (P = 0.84), activity (P = 0.08), worry 
(P = 0.64) and emotional symptoms (P = 0.8) did 
not show a significant change after 12 weeks, in the 
control group.
In the case group there was a significant decrease 
in abdominal symptoms (P < 0.001), activity (P < 
0.001), worry (P < 0.001) and emotional symptoms 
(P < 0.001) after our intervention but no significant 
change was observed in systemic symptoms and 
fatigue in this group.
Using the Mann-Whitney test, we found a 
difference in three aspects between the cases and the 
controls after our intervention including abdominal 
symptoms (P = 0.01), worry (P < 0.001) and 
emotional symptoms(P < 0.001). The other aspects 
did not show any significant difference between the 
two groups.
The minimum quality of life score was 29 in this 
study and the maximum was 203. The mean quality 
of life scores in our controls was 154.5 before the 
study and 136.9 after 12 weeks but the Wilcoxon 
test did not show significant change between the two 
(P = 0.143).
In our cases, a quality of life score of 158.6 before 
intervention had increased to 170 after 12 weeks, 
which was found to be significant using the Wilcoxon 
test (P < 0.001). Our data show that before treatment 
there had not been a significant difference between 
the two groups in quality of life scores (P = 0.351) but 
after intervention this difference becomes significant 
(P < 0.001).
Discussion
In this study the mean quality of life score in our 
controls was decreased after 3 months from 154 to 
137 which had been shown in other studies. In 2005, 
a study of different antiviral treatments on patients 
with hepatitis C by Kang and his colleagues showed 
Table 1. Demographic information of our studied 
population.
Control 
Group
Case Group P-value   
Statistical 
Test
Age 37.2 ± 9.5 40.3 ± 14.9 0.33 t- test
Sex (Percent) 0.381 chi-square
Male 24 (80%) 22 (73.3%)
Female 6 (20%) 8 (26.7%)
Level of Education fisher’s exact
Illiterate 0 3 (10%) 0.19
Primary and 
Guidance School
15 (50%) 16 (53.3%)
Diploma and 
Higher
15 (15%) 11 (36.7%)
Marital Status chi-square
Single 15 (50%) 13 (43.3%) 0.398
Married 15 (50%) 17 (56.6%)
Number of Children chi-square
3 or less 28 (93.3%) 23 (76.7%) 0.145
More than 3 2 (6.7%) 7 (23.3%)
Occupation fisher’s exact
Worker 7 (23.3%) 4 (13.3%) 0.076
Employee 4 (13.3%) 6 (20%)
Housekeeper 4 (13.3%) 4 (13.3%)
Student 0 6 (20%)
Retired 15 (50%) 10 (33.3%)
Duration of Disease chi-square
1-3 yr 22 (73.3%) 21 (70%) 1
3-6 yr 4 (13.3%) 5 (16.7%)
More than 6 yr 4 (13.3%) 4 (13.3%)
Hospitalization fisher’s exact
None 28 (93.3%) 30 (100%) 0.492
Once 2 (6.72%) 0
Hepatitis Type chi-square
Hepatitis C 20 (66.7%) 24 (80%) 0.243
Hepatitis B 10 (33.3%) 6 (20%)
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that all treatment regimens had reduced the quality 
of life of patients in the primary stages of treatment 
and side effects had reduced their compliance 
and adherence to treatment; whereas providing 
information to the patients about their treatment 
and its side effects will increase their tolerance, 
compliance and adherence to antiviral therapy (17). 
In our cases, the mean quality of life score increased 
to 170 from its original 158 after three months. This 
increase is in accordance with previous studies on 
patients with liver disease in Tehran and Shiraz (16, 
18).
Certain aspects in our control group did not 
show an increase after 12 months while the systemic 
symptoms showed a decrease during follow up. 
Previous studies show that the quality of life of the 
patient under antiviral treatment decreases in 12-24 
weeks after initiation of therapy and will eventually 
return to its baseline measurement after 24 weeks 
(12). Fatigue is a frequent side effect of hepatitis 
treatment and may result in early termination of 
antiviral therapy (12).
In our cases, there was an increase in the scores 
of abdominal symptoms, worry and emotional 
symptoms after 12 weeks. In our study, the quality 
of life score in our cases showed a significant increase 
after 12 weeks compared to the controls.
It seems that using simple measures against side 
effects like adequate hydration, light-to- moderate 
physical activity, scheduling the treatments for times 
when patients have less work or on weekends, using 
sedatives, antipyretics and similar measures will 
greatly help the control of side effects which will 
consequently increase the satisfaction and quality of 
life of patients and ultimately result in tolerance of 
the treatment (19).
One of the drawbacks of this study is the limited 
number of the population studied, which should 
be kept in mind in drawing a final conclusion. 
Another point to be considered is the different 
treatment regimens in hepatitis B and C (Interferon 
alpha and Ribavirin in hepatitis C and Interferon 
alpha in hepatitis B) which was a factor not taken 
into account in this study. The effect of different 
treatment regimens on hepatitis B and C could be 
the subject of a separate study. Emotional symptoms 
were different before intervention in the case and 
control groups, but a significant increase in the 
quality of life score could justify a faster and greater 
increase in the emotional aspect.
Table 2. Quality of Life scores before and after 12 weeks within groups.
Control 
Wilcoxon Test
Case
Wilcoxon Test
Before After Before After
Scores Min-Max Mean SD Mean SD P Mean SD Mean SD P
Abdominal Symptoms 3-21 15.9 5.3 15.9 5.6 0.48 17.7 3.1 19.5 3.2 0.00
Activity 3-21 19.8 1.9 18.7 2.7 0.01 20 1.9 18 3.6 <0.001
Fatigue 5-35 23.4 8 23 7.2 0.68 26.3 6.3 26 6.9 0.08
Systemic Symptoms 5-35 28.5 5.2 26.4 6.6 0.03 29.9 4.1 29.1 5.1 0.29
Emotional 8-56 33.3 9.9 33 9.2 0.03 40.1 9.2 46.5 10.6 <0.001
Worry  5-35 22.3 6.8 21.9 7.4 0.21 24.1 5.3 30.2 6.3 <0.001
Total Score 29-203 154.5 28.5 136.9 30.6 158.6 21.4 170 23.6
Table 3. Quality of Life scores before and after 12 weeks between two groups.
Before Intervention Mann-
Whitney Test
After Intervention Mann-
Whitney TestControl Case Control Case
Scores Min-Max Mean SD Mean SD P Mean SD Mean SD P
Abdominal Symptoms 3-21 15.9 5.3 17.7 3.1 0.43 15.9 5.6 19.5 3.2 0.94
Activity 3-21 19.8 1.9 20 1.9 0.8 18.7 2.7 18 3.6 0.08
Fatigue 5-35 23.4 8 26.3 6.3 0.26 23 7.2 26 6.9 0.84
Systemic Symptoms 5-35 28.5 5.2 29.9 4.1 0.35 26.4 6.6 29.1 5.1 0.04
Emotional 8-56 33.3 9.9 40.1 9.2 0.006 33 9.2 46.5 10.6 0.8
Worry  5-35 22.3 6.8 24.1 5.3 0.06 21.9 7.4 30.2 6.3 0.64
Total Score 29-203 154.5 28.5 158.6 21.4 136.9 30.6 170 23.6
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Conclusions
This study showed that continuous education 
and follow up in chronic hepatitis B and C patients 
under Interferon alpha treatment could greatly 
increase their adherence to interferon treatment and 
decrease the side effects, ultimately resulting in a 
better quality of life.
Acknowledgements
This study has made use of a grant from Tehran 
University of Medical Sciences and Baqiyatallah 
Research Center for Gastroenterology and Liver 
Disease. The authors hereby wish to thank the patients 
for their kind cooperation in this study. In addition, 
the authors would like to thank the Farzan Institute 
for Research and Technology for technical assistance.
References
1. Alavian SM, Adibi P, Zali MR. Hepatitis C virus in Iran: 
Epidemiology of an emerging infection. Arch Iran Med. 
2005;8:84-90.
2. Alavian SM, Ahmadzad Asl M, Lankarani KB, Shahbabaie 
MA, Bahrami Ahmadi A. Hepatitis C Infection in the 
General Population of Iran: A Systematic Review. Hepat 
Mon. 2009;9(3):211-23.
3. Alavian SM. Control of Hepatitis C in Iran: Vision and 
Missions. Hepat Mon. 2007;7(2):57-558.
4. Alavian SM, Hajariazdeh B, Ahmadzad Asl M, Kabir A, 
Bagheri Lankarani K. Hepatitis B Virus Infection in Iran: 
A Systematic Review. Hepat Mon. 2008;8(4):281-94.
5. Alavian SM. Optimal Therapy for Hepatitis C. Hepat Mon. 
2004;4(2):41-2.
6. Alavian S. What to Treat with Interferon? Hepat Mon. 
2004;4(6):23-9.
7. Davis GL, Balart LA, Schiff ER, et al. Assessing health-
related quality of life in chronic hepatitis C using the 
Sickness Impact Profile. Clin Ther. 1994;16(2):334-43.
8. Ware JE, Jr., Bayliss MS, Mannocchia M, Davis GL. 
Health-related quality of life in chronic hepatitis C: impact 
of disease and treatment response. The Interventional 
Therapy Group. Hepatology. 1999;30(2):550-5.
9. Niederau C, Bemba G, Kautz A. [Socioeconomic 
characteristics, quality of life, and state of knowledge 
of patients with hepatitis C viral infection in Germany-
-socioeconomic aspects in hepatitis C]. Z Gastroenterol. 
2006;44(4):305-17.
10. Bagheri-Lankarani K. How to manage side effects of 
interferon alpha therapy in Chronic Hepatitis C? Hepat 
Mon. 2004;4(6):5-8.
11. Pawlowska M, Halota W. [The adherence in the treatment of 
chronic hepatitis C]. Pol Merkur Lekarski. 2005;18(106):469-
72.
12. Bernstein D, Kleinman L, Barker CM, Revicki DA, Green 
J. Relationship of health-related quality of life to treatment 
adherence and sustained response in chronic hepatitis C 
patients. Hepatology. 2002;35(3):704-8.
13. Alavian SM, Foroutan H, Mirmomen S, Ghofrani H, Kabir 
A. Efficacy and safty of combination therapy of interferon-
alfa 2b plus ribavirin for chronic hepatitis C. MJIRI. 
2006;19(4):291-5.
14. Kolor B. Patient education and treatment strategies 
implemented at a pharmacist-managed hepatitis C virus 
clinic. Pharmacotherapy. 2005;25(9):1230-41.
15. Zandi M, Alavian SM, Memarian R, Kazem Nejad M. 
Assement of the effect of self care program on quality of life in 
patients with cirrhosis referred to Tehran Hepatitis Center in 
2003 [in Persian]. J Iran Univ Med Sci. 2004;11(41):411-22.
16. Zandi M, Adib-Hajbagheri M, Memarian R, Nejhad AK, 
Alavian SM. Effects of a self-care program on quality of life 
of cirrhotic patients referring to Tehran Hepatitis Center. 
Health Qual Life Outcomes. 2005;3:35.
17. Kang SC, Hwang SJ, Lee SH, Chang FY, Lee SD. Health-
related quality of life and impact of antiviral treatment in 
Chinese patients with chronic hepatitis C in Taiwan. World 
J Gastroenterol. 2005;11(47):7494-8.
18. Sharif F, Mohebbi S, Tabatabaee HR, Saberi-Firoozi M, 
Gholamzadeh S. Effects of psycho-educational intervention 
on health-related quality of life (QOL) of patients with 
chronic liver disease referring to Shiraz University of 
Medical Sciences. Health Qual Life Outcomes. 2005;3:81.
19. Fried MW. Side effects of therapy of hepatitis C and their 
management. Hepatology. 2002;36(5 Suppl 1):S237-44.
